Data suggest that the inhibition of SLC30A8, which encodes ZnT8, is a safe and effective potential therapy for treatment or prevention of type 2 diabetes #T2D #DiabetesResearch https://t.co/Im4ny2kUxs 🔓

📊 RCT - Safe Deprescribing in Older Adults with T2 Diabetes 📌 A low-cost previsit activation tool improves deprescribing in older adults with T2D—without increasing severe hypoglycemia. #DiabetesCare #Deprescribing #OlderAdults #PatientSafety https://t.co/Tkt5cBq8az

Please show your support for our sponsors today and pay a visit to the meeting's exhibition area. ℹ️ Catch up on the latest product information 💬 Meet representatives #ABCDMidlands25

📊 Meta-analysis of 10 GLP-1RA RCTs · ↓ MACE by 14% · ↓ HF hospitalisation + kidney outcomes 👉 Glycaemic control, not weight loss, associated with CV benefits of GLP-1RAs https://t.co/lEINyKUKUJ

Three types of Hunger and their mechanisms. It is important for Metabolic Physicians to understand the physiology whilst managing people with obesity.

New—Glucocorticoid-induced osteoporosis: novel concepts and clinical implications https://t.co/ZmMFAOJSc4 #OpenAccess

Understanding the cause of type 2 #diabetes https://t.co/IeBziX2C20 #T2D #remission #EASD2025

Phase 3 trial just published in @NEJM for #orforglipron, an oral GLP-1 medication for obesity. At the highest dose, participants saw an average 11.2% weight loss, with 36% losing at least 15% and 18% losing at least 20% of their body weight. Cardiometabolic markers also improved.

Once-weekly semaglutide 7·2 mg in adults with #obesity (STEP UP): a randomised, controlled, phase 3b trial https://t.co/yWo7Enmj8E #Obesity #EASD2025

🚨 A first at #EASD2025! @EASDnews unveils its first clinical practice guideline on the assessment & management of #diabetesdistress. The #clinicalguideline is now open for consultation. Please scan the QR code or click to give your feedback 📷 https://t.co/O0jNyJy1Hs #Diabetes

Type 2 #diabetes #subtypes classification: a global reckoning with #heterogeneity https://t.co/9n3lXTZgvd #T2D #FREE to read with registration (also FREE) #EASD2025

Join us at SAHF's 26th Conference. Prof Pratik Choudhary will dive into 'technology & how it is transforming management of Diabetes’ To see Pratik discuss this topic, book your free spot now here! https://t.co/gYlRsSPrgz @drpratikc @kamleshkhunti @docwas @AliaGilani @ShivaniM_KC

Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials 🔗 https://t.co/RcsGO4Eu9K

The A–G Mnemonic A Practical Framework for Deprescribing in Older Adults With Type 2 Diabetes by @AskDrShashank et al https://t.co/p9MSWToEuD @DiabetesCareADA

📊 In adults with obesity/overweight without T2 diabetes Tirzepatide over 72 weeks improved insulin sensitivity & β-cell function. 🧬 Insulin sensitivity ↑ mostly linked to weight loss 🧪 β-cell function ↑ largely due to tirzepatide itself https://t.co/ZTB11VBzlA

Effective treatments for pediatric obesity include FDA-approved obesity medications and bariatric surgery and are important tools for treating youth with type 2 diabetes. @ADA_Pubs Read Here➡️ https://t.co/994VjPFiik

A systematic evaluation confirming that multimodal interventions, especially multicomponent exercise programs are most effective at reducing frailty, compared with single component approaches. #Frailty #Geriatrics

Frailty is the leading geriatric syndrome and remains poorly understood worldwide. The new @TheLancet Commission calls for urgent action to reorient public health, clinical practice & policy to prevent & better manage frailty across the life course.

📌 At #ADA2025 Once-weekly insulin efsitora alfa versus once-daily insulin glargine in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a randomised clinical trial https://t.co/8E7TRb8K8A @AmDiabetesAssn

Presented at #ADASciSessions: In QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results: